News

Reverdia and Helm join forces
Enlarge image

BusinessNetherlandsFranceGermany

Reverdia and Helm join forces

18.10.2012 - Reverdia and Helm have partnered to market the bioplastics compound succinic acid on industrial scale.

Reverdia, the joint venture from Dutch DSM and French Roquette, has joined forces with Hamburg-based Helm AG for production and marketing in the highly competitive European market for bio-based succinic acid. The chemical building block for bioplastics, organic solvents and elastic fibres, is predicted to reach sales of 4-7bn annually in the mid-term.

„Reverdia’s Biosuccinium does not only offer an alternative to petrochemical succinic acid, but also for other fossil-based acids like adipic acid, so the market potential is huge”, stressed Christina Wienholz, Senior Executive Manager at Helm, who will take the part of marketing. “Our partnership with Helm will deliver expanded market development capacity for Reverdia in Europe“, said Reverdia chief Jo Kockelkoren, whose company has set up a plant-derived sugar fermentation process in yeast. His company aims at becoming the first company in the world to produce succinic acid on commercially large scale. Reverdia plans to complete a production plant with an annual capacity of 10,000 metric tons in Cassano Spinola, Italy, at the end of this year.

The move came just a week after German chemical major BASF and its Dutch partner Purac N.V. announced a joint-venture named Succinity to produce and market succinic acid. The companies want to start production after reconstruction of a 10,000 ton plant near Barcelona is finished in late 2013. US firm Myriant Inc. has also announced completion of construction of a 13,000 ton bio-succinic acid production plant in Quincy, Massachusetts, for the end of 2012. Bioamber Inc. is already marketing the bio-based compound since 2011, which is produced from E. coli in its Pomacle plant (France) that has an annual capacity of 2,000 metric tons. Succinity, however, may have a competitive edge because its process can also use glycerol, a byproduct of biodiesel production, as a feedstock.

According to the companies, biosuccinic acid could be used to produce coolants, surfactants, adhesives, corrosion inhibitors, lubricants, photo development fluids, herbicides, soldering pastes, runway deicers, polyurethanes, coating resins, phthalate-free plasticizers, polybutylene succinate (PBS) and many others.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-and-helm-join-forces.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.16 EUR46.2%
  • FORMYCON10.90 EUR38.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.59 EUR-10.7%
  • ADDEX2.99 CHF-9.4%

TOP

  • SANTHERA92.95 CHF2525.7%
  • CO.DON2.65 EUR154.8%
  • BB BIOTECH183.40 EUR63.9%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-48.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014